Better Biotechnology ETF: First Trust FBT vs. VanEck BBH

The performance gap is a weak basis for choosing a fund by itself: it describes one trailing window, not a durable edge, and the comparison does not establish how much came from constituent selection, weighting, or biotech-factor exposure. The more important distinction is portfolio behavior. FBT’s equal-weight design should make returns more responsive to broadening risk appetite and positive company-specific clinical or regulatory catalysts, but it also spreads exposure toward businesses whose funding access and binary milestones can matter more. BBH’s mega-cap tilt may be relatively resilient if investors retreat from smaller, less-proven biotech exposure, while limiting participation if gains broaden down-cap. FBT’s higher historical beta reinforces that it is not simply the lower-risk choice despite the reported five-year drawdown comparison; different windows and measures need not agree.

Near term, there is no compelling trade from these trailing returns alone. Over 1–3 months, monitor biotech breadth, clinical readouts, FDA decisions, and financing conditions; over 6–18 months, sustained improvement in funding and risk appetite would be a more credible tailwind for FBT’s broader exposure. The contrarian point: FBT’s past outperformance may be drawing investors toward a recent winner just as equal-weight rebalancing and constituent-specific setbacks can reverse relative performance. Verify current holdings overlap, spreads, and index-rebalance rules before sizing a relative-value position.